Loading company…
Barcelona-based biotech developing OXO-001, an oral drug designed to improve embryo implantation for women with infertility.
OXOlife SL primarily develops OXO-001, a first-in-class oral drug that targets the endometrium to enhance embryo implantation and improve pregnancy rates for women facing infertility, including those with PCOS. Its customers are fertility clinics and healthcare providers offering assisted reproductive technologies. Founded in 2013 in Barcelona, Spain, the company has raised EUR 5.00 mn, most recently a EUR 2.40 mn grant from the Spanish Science and Innovation Ministry in December 2022.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in